Biolegend, 100723, Alexa Fluor® 488 anti-mouse CD8a Antibody, 100μg

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested 3D IHC - Verified
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses
Excitation Laser: Blue Laser (488 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Moderzynski K, et al. 2016. PLoS Negl Trop Dis. . PubMed Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed Diamantopoulou Z, et al. 2022. Nature. 607:156. PubMed Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed Pani F, et al. 2021. Endocrinology. 162:. PubMed Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed Pinto NA, et al. 2023. Cell Death Differ. :. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed Onishi S, et al. 2015. PLoS One. 10:126564. PubMed Tang B, et al. 2020. Clin Cancer Res. 26:2216. PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed Yang H, et al. 2015. Cancer Res . 75: 3812-3822. PubMed Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed Bartkowiak T, et al. 2015. Proc Natl Acad Sci U S A. 112: 5290-5299. PubMed Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed Chen C, et al. 2019. Cell Rep. 29:4200. PubMed An J, et al. 2022. iScience. 25:103570. PubMed Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed Yamada T, et al. 2016. J Immunol. 197: 4079 - 4089. PubMed Glassman CR, et al. 2021. eLife. 10:00. PubMed Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed Xiong H, et al. 2021. Theranostics. 11:1594. PubMed Reinfeld BI, et al. 2021. Nature. 593:282. PubMed Kim S, et al. 2021. Elife. 10:. PubMed Ma S, et al. 2022. Cell Rep. 38:110520. PubMed Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed Collins N, et al. 2016. Nat Commun. 7:11514. PubMed Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed Mantilla-Rojas C, et al. 2022. Cancers (Basel). 14:. PubMed Sun J, et al. 2020. Cell. 182:734. PubMed Lee C, et al. 2009. Clin Cancer Res. 2.538888889. PubMed Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed Kaddatz H, et al. 2020. Glia. 69:925. PubMed Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed Klose R, et al. 2016. Nat Commun. 7:12528. PubMed Zhu J et al. 2017. Cell stem cell. 20(3):374-384 . PubMed Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed Simula L, et al. 2022. Mol Oncol. 16:188. PubMed Simula L, et al. 2020. Cell Death Differ. 27:2749. PubMed Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed
RRID: AB_493423 (BioLegend Cat. No. 100726) AB_389304 (BioLegend Cat. No. 100723)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ